Skip to main content
Clinical Trials/NCT01983566
NCT01983566
Terminated
Phase 1

Investigation of the Effect of Food and of Increased Gastric pH on the Relative Bioavailability of Deleobuvir Following Single Oral Administration in Healthy Caucasian and Japanese Subjects (an Open-label, Randomised, Four-way Crossover Study)

Boehringer Ingelheim1 site in 1 country16 target enrollmentNovember 2013

Overview

Phase
Phase 1
Intervention
BI 207127
Conditions
Healthy
Sponsor
Boehringer Ingelheim
Enrollment
16
Locations
1
Primary Endpoint
AUC(0-tz)
Status
Terminated
Last Updated
9 years ago

Overview

Brief Summary

The purpose of this trial is to investigate the effect of food with different fat content and of gastric pH increase (mediated by multiple dosing of omeprazole) on the relative bioavailability of deleobuvir.

Registry
clinicaltrials.gov
Start Date
November 2013
End Date
January 2014
Last Updated
9 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

BI 207127 fasted

patient to receive BI 207127 as a single dose in fasted state

Intervention: BI 207127

BI 207127 high fat

patient to receive BI 207127 as a single dose after a high fat breakfast

Intervention: BI 207127 high fat

BI 207127 low fat

patient to receive BI 207127 as a single dose after a low fat breakfast

Intervention: BI 207127 low fat

BI 207127 with Omeprazole

patient to receive BI 207127 as a single dose after 4 days treatment with Omeprazole 40 mg once a day

Intervention: BI 207127 with Omeprazole

Outcomes

Primary Outcomes

AUC(0-tz)

Time Frame: 1 hour (h) before drug administration and 30 minutes (min), 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h and 48h after drug administration

Area under the concentration-time curve of deleobuvir in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)

Cmax

Time Frame: 1 hour (h) before drug administration and 30 minutes (min), 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h and 48h after drug administration

Maximum measured concentration of deleobuvir in plasma (Cmax)

Secondary Outcomes

  • AUC(0-inf)(1 hour (h) before drug administration and 30 minutes (min), 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h and 48h after drug administration)

Study Sites (1)

Loading locations...

Similar Trials